Full-Time

Product Director

Marketing Engagement & Education

Updated on 7/21/2026

Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

Horsham, PA, USA

Hybrid

Three days in-office per week in Horsham, PA; up to 15% travel (limited international travel).

Category
Growth & Marketing (1)
Required Skills
Sales
FDA Regulations

Get referred to Johnson & Johnson

Find people who can refer or advise you

Requirements
  • A minimum of a bachelor’s degree is required.
  • A minimum of 7 years of progressive pharmaceutical or healthcare commercial experience is required, with experience in Sales, Sales Training, Professional Education, Operations, Brand Marketing, and/or Sales Management.
  • Practical knowledge of pharmaceutical marketing, FDA regulatory and legal requirements, and health care compliance regulations (HCC regulations) is required.
  • Ability to assess brand and portfolio needs in partnership with business leaders and translate strategy into education solutions that support enterprise priorities.
  • Experience developing and executing Marketing Engagements & Education strategies across speaker bureau, sponsorships, advisory boards, fee-for-service, and purchase order coordination.
  • Highly organized and detail-oriented with demonstrated ability to manage multiple large-scale programs, competing priorities, and complex operational workstreams simultaneously.
  • Proven budget management and financial stewardship experience, including planning, vendor oversight, resource prioritization, and disciplined tracking of spend against business priorities.
  • Strong executive communication skills, with the ability to synthesize complex information, develop concise recommendations, and secure alignment with senior leaders and cross-functional partners.
  • Demonstrated people leadership experience, including coaching, talent development, performance management, engagement, and building high-performing teams.
  • Ability to lead strategically through influence, operate effectively in matrixed and ambiguous environments, and simplify complexity into clear strategies, actionable plans, and aligned leadership decisions.
  • Ability to identify, establish, and grow relationships with third-party partners whose capabilities complement internal core competencies.
  • Excellent written, verbal, and presentation skills.
  • Strong interpersonal flexibility and ability to engage effectively with a broad range of stakeholders.
Responsibilities
  • Lead the Hematology pillar of MEET in partnership with the Director, Marketing Engagements & Education, with accountability for strategy, operating discipline, and executional excellence across speaker bureau, sponsorships, advisory boards, fee-for-service, and purchase order coordination.
  • Set a clear vision for MEET Hematology, translate strategy into actionable priorities, and provide strong people leadership through coaching, performance management, talent development, and team engagement.
  • Serve as a trusted strategic partner to Hematology Marketing and Sales Leadership, ensuring priorities are aligned, decisions are clear, and execution is connected to business objectives.
  • Lead budget stewardship, vendor management, and internal and external stakeholder engagement with disciplined oversight of planning, spend, prioritization, issue resolution, audits, escalations, policies, procedures, and training.
  • Partner with the contracted business partners to hire, performance manage, and develop contracted colleagues supporting sponsorship, advisory boards, fees for services and purchase order coordination activities.
  • Collaborate with Commercial Excellence, Compliance, Legal, JJIT Speaker Bureau Therapeutic Area Leads, and the single-source Speaker Bureau vendor to enhance speaker bureau processes, policies, and systems across JJIT.
  • Operational Excellence: Lead disciplined execution of Hematology Speaker Programs and Sponsorships in accordance with J&J standard operating procedures. Apply strong operational judgment, attention to detail, risk management, and continuous improvement discipline to strengthen quality, consistency, and efficiency. Identify opportunities to improve policies, procedures, technology, and resources that support speaker bureau, sponsorships, and lifecycle management initiatives. Partner across MEET leadership and Solid Tumor counterparts to standardize processes where appropriate across Hematology, Solid Tumor, and PS&E Marketing.
  • Strategic Project Management: Develop and manage integrated timelines, action plans, governance routines, and decision pathways with Hematology cross-functional partners to ensure all deliverables are achieved with quality and accountability.Synthesize complex inputs into clear recommendations and decision-ready updates for senior leaders. Oversee speaker training, meetings, event coordination, communications, registration, calendar management, program logistics, budgets, administrative activities, tactical deployment, and external agency execution.
  • Enterprise Alignment: Drive alignment on speaker program and sponsorship priorities across Brand Marketing, Strategic Marketing, Thought Leader Engagement, Health Care Compliance, Legal, Sales, Sales Training, Business Analytics, Strategic Customer Group, Medical Affairs, North America Pharma Affiliates, Alliance Management, Communications, Corporate teams, and external vendors. Clarify decision rights, surface risks and barriers, and execute practical solutions that advance enterprise priorities.
  • Stakeholder Experience: Identify and implement innovative, industry-leading practices that enable consistent, effective, and impactful experiences across speaker programs and sponsorship engagements. Assess current tools and resources, identify gaps and improvement opportunities, and evaluate new capabilities that enhance execution for the US Hematology Oncology organization.
  • Compliance: Ensure strict adherence to legal, regulatory, medical education, and procurement compliance requirements.
  • Develop broad enterprise leadership capabilities through exposure to marketing, operations, compliance, field engagement, vendor partnerships, and cross-functional business priorities.
  • Bring a forward-looking mindset that challenges the status quo, elevates ways of working, and strengthens how the organization operates and delivers impact.
  • Perform other duties as assigned.
Desired Qualifications
  • MBA or advanced degree in a related field.
  • Oncology experience.
  • Experience working across sales, marketing, training, and/or medical education.
  • Experience leading continuous improvement initiatives and sharing best practices.
  • Knowledge of internal systems, including Totality, ARIBA, IMPROVE, iMedical, and CentrisDirect.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • J&J's stock surged 47.1% over the past year, outperforming the healthcare sector.
  • FDA approved J&J's Dual Energy cardiac ablation platform for electrophysiology in 2026.
  • J&J's 2026 revenue will exceed $100 billion for the first time in history.

What critics are saying

  • 58,206 pending talc ovarian cancer lawsuits risk multi-billion payouts within 12–24 months.
  • Eli Lilly's obesity drugs dominate 56% of its revenue, eroding J&J's pharma growth.
  • Abiomed's Impella trial failure forces J&J's cardiovascular unit to contract by 10–15%.

What makes Johnson & Johnson unique

  • J&J uniquely spans pharmaceuticals, MedTech, and consumer health across 140 years.
  • Its Dual Energy THERMOCOOL platform delivers both radiofrequency and pulsed field energy.
  • J&J raised 2026 revenue guidance to $100.8–$101.4 billion after Q2 beat.
  • J&J's oncology portfolio gained multiple FDA approvals in early 2026.
  • MedTech growth is fueled by Shockwave (2024) and Abiomed (2022) acquisitions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-3%

2 year growth

-1%
Johnson & Johnson
Jun 8th, 2026
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

• Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers • Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key limitations of existing therapeutic approaches • Strengthens leadership in next-generation antibody engineering to accelerate oncology innovation

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.